← ANALYST RATINGS · TIPRANKS
Travere Therapeutics (TVTX): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy1 Hold0 Sell
Ratings of 12 analysts in the last 3 months · top analysts only12-month forecast
Based on 12 price targets given in the last 3 months, the average target is $75.92, the highest $90.00, the lowest $62.00. The average is +53.1% from the last price of $49.60.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $55.00 → $56.00+1.8% | Hold | +12.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $53.00 → $54.00+1.9% | Hold | +8.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $54.00 → $55.00+1.9% | Hold | +10.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $52.00 → $53.00+1.9% | Hold | +6.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $56.00 → $58.00+3.6% | Hold | +16.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $55.00 → $56.00+1.8% | Hold | +12.9% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $80.00 | Buy | +61.3% | Reiterated | 15.10.26on TipRanks 07:36 | −1.2%next day −4.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $56.00 → $55.00−1.8% | Hold | +10.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $54.00 → $53.00−1.9% | Hold | +6.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $53.00 → $52.00−1.9% | Hold | +4.8% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $57.00 → $56.00−1.8% | Hold | +12.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $57.00 → $56.00−1.8% | Hold | +12.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $55.00 → $54.00−1.8% | Hold | +8.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $56.00 → $54.00−3.6% | Hold | +8.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $54.00 → $53.00−1.9% | Hold | +6.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $58.00 → $57.00−1.7% | Hold | +14.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $57.00 → $55.00−3.5% | Hold | +10.9% | Reiterated | 11.10.26on TipRanks 00:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $60.00 → $57.00−5.0% | Hold | +14.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $58.00 → $55.00−5.2% | Hold | +10.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $58.00 → $56.00−3.4% | Hold | +12.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $57.00 → $54.00−5.3% | Hold | +8.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $61.00 → $58.00−4.9% | Hold | +16.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $61.00 → $57.00−6.6% | Hold | +14.9% | Reiterated | 09.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $60.00 → $61.00+1.7% | Hold | +23.0% | Reiterated | 07.10.26on TipRanks 00:05 | — | |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $89.00 | Buy | +79.4% | Reiterated | 06.10.26on TipRanks Oct 7 07:11 | −3.5%next day −4.3% · 5 days −7.3% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $68.00 → $60.00−11.8% | Hold | +21.0% | Reiterated | 03.10.26on TipRanks 00:05 | — | |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $67.00 | Buy | +35.1% | Reiterated | 02.10.26on TipRanks 12:05 | −0.6%next day +0.6% · 5 days −9.6% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $75.00 → $89.00+18.7% | Buy | +79.4% | Reiterated | 23.09.26on TipRanks Sep 24 07:10 | 0.0%next day +1.4% · 5 days −0.9% | ↗ |
| Jason Zemansky★★★★★★★★★★#467 · hits 60% · avg +21.6% | Bank of America Securities | $71.00 | Buy | +43.1% | Reiterated | 23.09.26on TipRanks Sep 24 05:25 | 0.0%next day +1.4% · 5 days −0.9% | ↗ |
| Joseph Pantginis★★★★★★★★★★#243 · hits 55% · avg +24.8% | H.C. Wainwright | $67.00 | Buy | +35.1% | Reiterated | 23.09.26on TipRanks Sep 22 06:45 | −4.1%next day 0.0% · 5 days +0.7% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $75.00 → $76.00+1.3% | Buy | +53.2% | Reiterated | 22.09.26on TipRanks 08:55 | −4.1%next day 0.0% · 5 days +0.7% | ↗ |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $60.00 → $68.00+13.3% | Hold | +37.1% | Reiterated | 20.08.26on TipRanks 00:05 | — | |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $49.00 → $68.00+38.8% | Buy | +37.1% | Reiterated | 17.08.26on TipRanks 07:22 | +2.7%next day +1.3% · 5 days +3.9% | ↗ |
| Edward Nash★★★★★★★★★★#204 · hits 52% · avg +29.5% | Canaccord Genuity | $70.00 | Buy | +41.1% | Reiterated | 11.08.26on TipRanks Aug 12 07:35 | −0.8%next day +3.0% · 5 days +6.5% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $68.00 → $78.00+14.7% | Buy | +57.3% | Reiterated | 10.08.26on TipRanks 08:25 | −0.7%next day −0.8% · 5 days +4.4% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $43.00 → $62.00+44.2% | Hold | +25.0% | Reiterated | 09.08.26on TipRanks 12:37 | −0.7%next day −0.8% · 5 days +4.4% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $53.00 → $90.00+69.8% | Buy | +81.5% | Reiterated | 06.08.26on TipRanks Aug 7 08:10 | −0.3%next day −2.4% · 5 days −2.8% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $65.00 → $80.00+23.1% | Buy | +61.3% | Reiterated | 06.08.26on TipRanks 07:15 | −0.3%next day −2.4% · 5 days −2.8% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $70.00 → $85.00+21.4% | Buy | +71.4% | Reiterated | 06.08.26on TipRanks Aug 5 06:35 | +12.2%next day −0.3% · 5 days −1.3% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $62.00 → $60.00−3.2% | Hold | +21.0% | Reiterated | 05.08.26on TipRanks 13:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $57.00 | Hold | +14.9% | Reiterated | 05.08.26on TipRanks 13:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $62.00 → $61.00−1.6% | Hold | +23.0% | Downgrade | 05.08.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $60.00 → $58.00−3.3% | Hold | +16.9% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $58.00 → $59.00+1.7% | Hold | +19.0% | Reiterated | 05.08.26on TipRanks 10:06 | — | |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | $60.00 → $75.00+25.0% | Buy | +51.2% | Reiterated | 04.08.26on TipRanks 22:52 | +12.2%next day −0.3% · 5 days −1.3% | ↗ |
| Prakhar Agrawal★★★★★★★★★★#1817 · hits 40% · avg +16.0% | Cantor Fitzgerald | — | Buy | — | Reiterated | 20.02.26on TipRanks Feb 23 12:05 | +3.0%next day +2.1% · 5 days −1.5% | ↗ |
| Joseph Schwartz★★★★★★★★★★#135 · hits 54% · avg +31.9% | Leerink Partners | — | Buy | — | Reiterated | 13.01.26on TipRanks 14:59 | −14.4%next day −0.1% · 5 days −1.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Travere Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $75.92 at a price of $58.88 (+28.9%); now: $75.92 at $49.60 (+53.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 0 | 0 | 0 | 2 |
| Buy | 30 | 42 | 34 | 33 | 23 | 18 |
| Hold | 2 | 2 | 1 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 22.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $0.03 (from $-0.95 to $0.84). Last quarter: $-0.37.
Sales
Next quarter’s sales estimate — $196M (from $157M to $240M). Last quarter: $170M.
Best top-analyst consensus in the sector · Healthcare
About Travere Therapeutics
- CEO: Eric Dube
- Employees: 497
- 3611 Valley Centre Drive, San Diego, CA, 92130, US
- www.travere.com
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Data from the stock’s TipRanks forecast page, read 52 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗